Evidence map›Paper›PMID 32457417›Full record

ArticleActa pharmacologica Sinica2021

Gasdermin E-derived caspase-3 inhibitors effectively protect mice from acute hepatic failure.

Wan-Feng Xu, Quan Zhang, Chu-Jie Ding, Hui-Yong Sun, Yuan Che, Hai Huang, Yun Wang, Jia-Wei Wu, Hai-Ping Hao, Li-Juan Cao

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. [Research progress in the role of caspaseZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Research Progress of Pyroptosis in Diabetic Kidney Disease.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Research Progress of Pyroptosis in Fatty Liver Disease.International journal of molecular sciences · 2023
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wan-Feng Xu *State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Quan Zhang *State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Chu-Jie DingState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Hui-Yong SunState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Yuan CheState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Hai HuangState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Yun WangState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Jia-Wei WuState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China.
Hai-Ping HaoState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China. haipinghao@cpu.edu.cn.
Li-Juan CaoState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing, 210009, China. caolijuan0702@cpu.edu.cn.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death (PCD), including apoptosis, apoptotic necrosis, and pyroptosis, is involved in various organ dysfunction syndromes. Recent studies have revealed that a substrate of caspase-3, gasdermin E (GSDME), functions as an effector for pyroptosis; however, few inhibitors have been reported to prevent pyroptosis mediated by GSDME. Here, we developed a class of GSDME-derived inhibitors containing the core structure of DMPD or DMLD. Ac-DMPD-CMK and Ac-DMLD-CMK could directly bind to the catalytic domains of caspase-3 and specifically inhibit caspase-3 activity, exhibiting a lower IC

Indexed as

Amino Acid Chloromethyl KetonesAnimalsApoptosisBile DuctsCaspase 3Caspase InhibitorsCell Line, TumorGasderminsHumansLigationLiver DiseasesMaleMiceMice, Inbred C57BLMolecular Docking SimulationOligopeptidesAmino Acid Chloromethyl KetonesCASP3 protein, humanCasp3 protein, mouseCaspase 3Caspase InhibitorsGasderminsGSDME protein, humanGsdme protein, mouseOligopeptidesPeptide FragmentsProtective AgentsReceptors, Estrogenacute hepatic failureapoptosiscaspase-3 inhibitorgasdermin Epyroptosis

Identifiers

PMID32457417
PMCPMC7921426
OpenAlexW3030012850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.